Pulmonary toxicity related to EGFR-TKI monotherapy or its combination with radia-tion as treatment for non-small cell lung cancer
10.3969/j.issn.1000-8179.2017.11.217
- VernacularTitle:EGFR-TKI单药或联合放疗治疗非小细胞肺癌肺毒性研究进展
- Author:
Zhiefeng NIE
- Keywords:
EGFR-TKI;
radiotherapy;
pulmonary toxicity;
NSCLC
- From:
Chinese Journal of Clinical Oncology
2017;44(11):558-561
- CountryChina
- Language:Chinese
-
Abstract:
Monotherapy of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) serves as the first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutation. Pre-clinical studies confirmed that TKIs can increase radiation sensitiv-ity. Clinical studies confirmed that EGFR-TKI combined with radiotherapy may improve survival of patients and can be used as alterna-tive to chemoradiotherapy. Pulmonary toxicity induced by EGFR-TKIs monotherapy features low incidence rate but high mortality rate, and the incidence rate raries when TKIs is combined with radiotherapy. In this review, we summarise related literature on pulmonary toxicity in EGFR-TKI monotherapy or its combination with radiotherapy for advanced NSCLC. This study can serve as reference for safe-ty of this combined therapy.
